NASDAQ OMX

Ratos: Euromaint avyttrar sin tyska verksamhet

28.12.2015 07:30 | NASDAQ OMX

Dela

Denna information offentliggörs enligt lagen om värdepappersmarknaden, lagen om handel med finansiella instrument eller krav ställda i noteringsavtal.

Ratos dotterbolag Euromaint, ett underhållsföretag för spårtrafikbranschen, har tecknat avtal om att sälja samtliga aktier i sitt tyska dotterbolag. Efter en längre tids svag utveckling i den tyska verksamheten har beslut fattats att fokusera på kärnverksamheten i Sverige. Avyttringen sker till Iberia Industry Capital Group och medför direkt en negativ resultateffekt i Euromaintkoncernen om cirka 200 Mkr. Avyttringen och den sammantaget svaga utvecklingen i Euromaint under en längre tid förväntas medföra en väsentlig nedskrivning av bolagets bokförda värde i Ratos vid årsbokslutet.

Euromaints tyska verksamhet har haft en svag utveckling under flera år och har på grund av projektförseningar och låga volymer haft en ytterligare negativ resultatutveckling under 2015. Avyttringen sker som ett led i att fokusera på den lönsamma svenska kärnverksamheten. Försäljningen, som innehåller sedvanliga villkor, bland annat om finansiering, beräknas slutföras under första kvartalet 2016. Försäljningen medför direkt en negativ resultateffekt i Euromaintkoncernen om cirka 200 Mkr. Avyttringen, i tillägg till den generellt svaga utvecklingen i Euromaint Tyskland och Sverige, förväntas även medföra en väsentlig nedskrivning av Ratos bokförda värde för Euromaint. Detta belopp avses att anges i samband med Ratos bokslutskommuniké. 

- Euromaint har under många år verkat på en mycket konkurrensutsatt marknad där särskilt den tyska verksamheten haft en negativ resultatutveckling. Denna avyttring möjliggör ett större fokus på den svenska kärnverksamheten, fortsatta åtgärder för högre kostnadseffektivitet och leverans av högkvalitativa tågunderhållstjänster, säger Susanna Campbell, VD Ratos.

Euromaint är Sveriges ledande oberoende underhållsföretag för spårtrafikbranschen. Tjänsterna och produkterna säkrar tillförlitligheten och livslängden för spårburna fordon såsom passagerartåg, lok, godsvagnar och arbetsmaskiner. Den svenska verksamheten omsatte under januari-september 2015 1 215 Mkr och EBITA uppgick till 65 Mkr. Antalet anställda uppgår till cirka 1200 med placering på flera orter i hela Sverige. Det bokförda värdet i Ratos för hela Euromaint inklusive den tyska verksamheten uppgick till 702 Mkr per den 30 september 2015. Ratos ägarandel i Euromaint är 100%.

För ytterligare information:
Susanna Campbell, VD, 08-700 17 00
Elin Ljung, Kommunikationschef, 08-700 17 20

Kommande informationstillfällen från Ratos:  
Bokslutskommuniké 2015 17 februari 2016
Årsstämma 2016 14 april 2016
Delårsrapport januari-mars 2016 10 maj 2016


Ratos äger och utvecklar onoterade medelstora företag i Norden. Målet är att som aktiva ägare bidra till långsiktig och hållbar företagsutveckling i bolagen samt att genomföra värdeskapande transaktioner. Ratos portfölj består av bolagen AH Industries, Aibel, ArcusGruppen, Biolin Scientific, Bisnode, DIAB, Euromaint, GS-Hydro, HENT, HL Display, Jøtul, KVD, Ledil, Mobile Climate Control, Nebula, Speed Group och TFS. Ratos är noterat på Nasdaq Stockholm och har totalt cirka 17 000 medarbetare.




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ratos via Globenewswire

HUG#1975915

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressmeddelande

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressmeddelande

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressmeddelande

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressmeddelande

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38Pressmeddelande

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressmeddelande

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum